Limelight Bio

Limelight Bio was founded in 2017 to overcome the major limitations of current gene therapy and gene editing approaches, expanding the range of diseases treatable by gene therapy. Limelight Bio is building an industry-leading platform to develop proprietary technologies, identify advanced targets, and discover drug candidates, aiming to treat more diseases for more patients. The company is pioneering gene correction in unprecedented areas, including proprietary methods to address large genetic defects regardless of gene size or mutation patterns, without causing permanent genomic alterations.